- Tytuł:
- Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
- Autorzy:
- Źródło:
- Clinical and Translational Oncology. February 2015 17(2):160-166
Czasopismo naukowe